Summary:
In patients with type 2 diabetic bone disease characterized by low bone turnover, treatment with recombinant human parathyroid hormone rhPTH(1-34) significantly improved bone turnover markers and clinical outcomes compared to alendronate therapy, though it was associated with adverse effects typical of PTH analogs such as transient hypercalcemia and injection site reactions.
| PICO | Description |
|---|---|
| Population | Adults diagnosed with type 2 diabetic bone disease exhibiting low bone turnover levels. |
| Intervention | Recombinant human parathyroid hormone rhPTH(1-34) administered subcutaneously; dosage as per study protocol. |
| Comparison | Alendronate treatment, standard antiresorptive therapy for diabetic bone disease; dosage per standard clinical practice. |
| Outcome | rhPTH(1-34) significantly increased bone turnover markers and improved bone quality compared to alendronate, with better clinical benefits in bone metabolism. However, rhPTH(1-34) was associated with side effects including transient hypercalcemia and injection site reactions. |
Source: Huijuan Li, et al. “Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease.” Read article here.
